Clinical Trials

Nabiximols Improve Spasticity Symptoms in Motor Neuron Disease

From Neurology Advisor: Nabiximols, a cannabidiol, reduced spasticity symptoms and was tolerable and safe when used in patients with motor neuron disease, according to a phase 2 trial published in Lancet Neurology. In this randomized, double-blind study (ClinicalTrials.gov identifier: NCT01776970), patients with possible, probable, or definite amyotrophic lateral sclerosis orRead More →

Evaluating the Therapeutic Potential of Cannabinoids: How to conduct research within the current regulatory framework [VIDEO]

On December 8, 2018, the following NIH-sponsored proceeding took place: “Evaluating the Therapeutic Potential of Cannabinoids: How to conduct research within the current regulatory framework“ From the website: The National Center for Complementary and Integrative Health (NCCIH), at the National Institutes of Health (NIH), sponsored a workshop on December 8,Read More →

Zelda Therapeutics Partners with St. Vincent's to Study Opioid Use Reduction

In a focused effort to study the potential impact cannabinoid-based medical interventions may have on reducing opioid use for pain reduction, Perth-based Zelda Therapeutics LTD has established a partnership with St. Vincent’s Hospital in Melbourne to conduct clinical trials to study potential uses for these treatments. Subjects who have becomeRead More →